Vertex Pharmaceuticals Incorporated VRTX

526.19 3.81 0.73% as of 25 Sep
Market cap
$132.3B
P/E
30.4×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Vertex Pharmaceuticals Incorporated (VRTX) Operating margin

Vertex Pharmaceuticals Incorporated's operating margin over the twelve months to 30 June 2026 was 38.0%, up 3.2 percentage points from fiscal 2025 (34.8%). Over the past ten years it has ranged from −45.2% (fiscal 2015) to 48.2% (fiscal 2022); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.

Operating margin, annual

Annual

Period Operating margin Change (points)
FY2025 34.8% 36.88
FY2024 −2.11% (40.94)
FY2023 38.8% (9.40)
FY2022 48.2% 11.50
FY2021 36.7% (9.30)
FY2020 46.0% 17.26
FY2019 28.8% 7.93
FY2018 20.8% 15.89
FY2017 4.95% 4.37
FY2016 0.58% 45.81

Quarterly

Period Operating margin Change (points)
Jun 2026 37.4% (0.70)
Mar 2026 38.1% 0.30
Dec 2025 37.8% (0.76)
Sep 2025 38.6% (0.27)
42 more quarters

Against its own ten years

Low −45.2% High 48.2%
Ten-year median 28.8%
Current reading's percentile 64

Operating margin against peers

Company Operating margin
RPRX Royalty Pharma PLC compare 59.6%
VRTX Vertex Pharmaceuticals Incorporated 38.0%
ARGX argenex SE compare 30.1%
REGN Regeneron Pharmaceuticals, Inc. compare 24.7%
ALNY Alnylam Pharmaceuticals, Inc. compare 20.8%
ONC BeOne Medicines Ltd. - Sponsored ADR compare 15.1%
RVMD Revolution Medicines, Inc. compare 0.00%
INSM Insmed, Inc. compare −73.9%
MRNA Moderna, Inc. compare −149.0%
Biotechnology industry median 0.00%
Healthcare sector median 0.00%
Market median 0.00%

What Operating margin is

EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.

EBIT ÷ Revenue

The full definition of Operating margin →

More on VRTX